Why does it affect memory in the same way as "Viagra"? Spotlight on a new drug candidate for Alzheimer's disease

Why does it affect memory in the same way as "Viagra"? Spotlight on a new drug candidate for Alzheimer's disease

When hearing "slowed progression by 31%," some people might wonder how much longer they can enjoy conversations with family or go shopping on their own. What this trial measured was not the remaining time for each individual, but the average change in scores related to memory and daily life over about a year.

On November 16, 2026, at an international conference on clinical trials for Alzheimer's disease held in Boston, USA, the South Korean pharmaceutical company AriBio announced the primary results of the Phase 3 trial of their oral medication "AR1001." The German newspaper WELT reported that a drug of the same type as Viagra, used for erectile dysfunction, might slow the progression of early Alzheimer's disease. The key to understanding the announcement lies in the two numbers: 604 and 1,535.


What does the "31%" figure compare?

The trial included 1,535 participants with early Alzheimer's disease from 13 countries. Participants took either AR1001 or a placebo without active ingredients once a day for 52 weeks. The measure used to assess the effect was called "CDR-SB," which scores how much memory, judgment, household activities, and personal care are affected.

The research team decided before starting the trial to examine not only the entire group of participants but also those who had not used existing dementia treatments, such as cholinesterase inhibitors or memantine, at the start. This condition applied to 604 people.

Among these 604 people, those who took AR1001 had an average deterioration over 52 weeks that was 0.44 points less than those who took the placebo. The "31% suppression" is expressed as a percentage based on the deterioration in the placebo group. It does not mean that 31% of the 604 people improved their symptoms.

On the other hand, across all participants, including these 604 people, the difference shrank to 0.11 points, about 7% in percentage terms, and was not statistically significant. The effect observed when used alone is worth further investigation. However, it cannot be concluded from this result alone that existing drugs weakened the effect of AR1001. It also does not justify stopping any current medication.


Why investigate a drug of the same type as Viagra?

Both Viagra and AR1001 share the commonality of inhibiting the enzyme "PDE5." The "cGMP" that this enzyme breaks down works not only when blood vessels expand but also when brain nerve cells exchange signals. Researchers focused on the potential effect on brain signals related to learning and memory, in addition to blood flow.

In fact, those who took AR1001 showed an increase in cGMP in their cerebrospinal fluid compared to the placebo group. Interestingly, this change was observed both in the group of 604 and in the entire group of participants. Although there was evidence that the drug targeted the intended mechanism, it was clearly reflected as a difference in cognitive or daily function in only one of the two analyses.

In this trial, patients took AR1001. Whether the same effect can be obtained by taking sildenafil, the active ingredient in Viagra, was not investigated in this trial.


On social media, there is anticipation for the pill, and readers ask, "How many years will it extend?"

The Dutch clinical research institution "Progress Clinical Research," which participated in the trial, expressed cautious optimism on LinkedIn. One positive aspect noted by the institution's neurologist, Niels Prins, was the form of a pill that can be taken daily. However, the same post also mentioned that clear effects were not demonstrated across all participants, and that detailed results, evaluations, and approvals are still needed before it becomes available for patient use.

In the comments section of WELT, there was another pressing question. One reader translated the numbers into time, wondering if symptoms that would progress in three years might extend to about four years with the medication. There were also jokes about the commonality with Viagra, and some readers questioned the headline that prompted such reactions.

"How many years will it extend?" is a natural question when considering daily life. However, the average score difference observed over 52 weeks cannot be directly extended to several years ahead. To know how much longer one can continue preparing meals or going out independently, longer follow-up is necessary.


What could oral medication change for Japanese patients and their families?

One of the drugs used in Japan to slow the progression of early Alzheimer's disease, donanemab, requires intravenous infusions at medical institutions every four weeks. In addition to the patient, accompanying family members also need to plan their schedules around these visits. If more treatments that can be taken at home become available, the burden of repeatedly visiting for infusions could change.

At the same time, whether one can continue taking a daily pill depends on more than just the convenience of a tablet. In this trial, the rate of serious adverse events was similar between the AR1001 group at 10.0% and the placebo group at 9.8%. However, diarrhea, dizziness, and falls were slightly more common in the AR1001 group, and 5.2% discontinued due to adverse events, exceeding the 1.7% in the placebo group.

AriBio plans to discuss the results with the U.S. Food and Drug Administration (FDA). What this announcement has revealed is the potential for oral medication to reduce deterioration over one year in some patients with early Alzheimer's disease. What patients and families want to know next is how long this difference lasts and what impact it will have on the daily activities that the patient values.

Source